



February
10

February 10, 2003, Park Hyatt San Francisco — San Francisco
European Regulatory Affairs: An In-Depth Review of Registration Procedures in the European Union

This Drug Information Association training course will cover the evolution of the registration systems available for approval of products since January 1995 in the European Union. Detailed review will be offered on centralized, mutual recognition, and national procedures and practical examples of product types suitable for each procedure will be discussed, as will the impact of the European Commission's interpretation of Article 7A and Article 9.

Other issues that impact successful regulatory strategy in Europe, such as Harmonization of Summary of Product Characteristics, Article 11 and Article 12, Pharmacovigilance, and Supplementary Protection Certificate for patents will be described. The workshop will provide practical advice on how to file applications for the marketing authorizations in the European Union for staff involved in International Regulatory Affairs. Regulatory strategy that affects commercial, business, and licensing arrangements will be of importance to those responsible for business development.

For more information, contact Dori Browning, Jenna Hannum, or Susan McLaughlin at 215-442-6100, e-mail training@diahome.org, or visit www.dia-home.org.

February
10

February 10-11, 2003, Coronado Island Marriott — San Diego
Cardiovascular Drug Discovery and Development Summit

Researchers in the cardiovascular field will convene to discuss the latest efforts in drug discovery and clinical development for the next generation of therapeutics.

Sponsored by Strategic Research Institute, highlights of the meeting will include "Clinical Development of Crestor," by AstraZeneca; "Nuclear Receptor PPAR in Macrophages Results in Reduced Inflammatory Response and Atherosclerotic Lesion," by The Salk Institute; and "Inhibition of ApoB-100 with Antisense Technology as a Therapeutic Strategy for the Treatment of Hyperlipidemias," by Isis Pharmaceuticals.

The list of presenters include: AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., Millennium Pharmaceuticals, Pharmacia Corp., Procter & Gamble Pharmaceuticals, Atherogenics, Collateral Therapeutics, CV Therapeutics, Isis Pharmaceuticals, Myogen, Sequenom, Texas Biotechnology, Purdue University, The Salk Institute, Scripps Research Institute, and Southwestern Medical Center.

For more information, contact Jon E. Liong, at 212-967-0095, ext. 243, e-mail jliong@srinstitute.com, or visit www.srinstitute.com.

February
18

February 18-21, 2003, Four Seasons Hotel — Boston
Postgraduate Course in Clinical Pharmacology, Drug Development, and Regulation

The Tufts Center for the Study of Drug Development is offering a four-day course in clinical pharmacology, drug development, and regulation. The program, presented in collaboration with the Drug Information Association, will provide an in-depth overview of drug development and regulation and focus on practical, theoretical, and technical issues.

This program is intended for clinical pharmacology, clinical development, marketing, and research and development professionals, as well as regulators, physicians, attorneys, consultants, and others working with the research-based drug industry.

For more information, contact Ellie Cleary, Tufts Center for the Study of Drug Development, at 617-636-2173, e-mail eleanor.cleary@tufts.edu, or visit csdd.tufts.edu.

February
20

February 20-21, 2003, Wyndham Emerald Plaza — San Diego
Inflammation in Drug Discovery and Development

The world inflammatory disease research community and Bristol-Myers Squibb, Novartis Pharmaceuticals, R.W. Johnson, AstraZeneca, and Amgen will convene at this year's Inflammation in Drug Discovery and Development event.

The conference, which will consist of seven inflammatory compound presentations, will explore in detail the research efforts to discover and develop safer and more effective therapies for rheumatoid arthritis and other inflammatory diseases, as well as programs intended to discover next generation anti-inflammatory drugs.

The conference is organized into four main sections: Novel Anti-TNF Proteins and Small-Molecule Inhibitors; Advances in IL-1, Gamma Interferon, and IL-2 Biologics; Novel B Cell, T Cell and Receptor Modulators; and Additional Approaches for Novel Anti-Inflammatory Drugs.

For more information, contact Ed Drilon, Strategic Research Institute, 212-967-0095, ext. 233, e-mail edrilon@srinstitute.com, or visit www.srinstitute.com.

February
24

February 24-28, 2003, Wyndham U.S. Grant — San Diego
Antibody World Summit

This series of four related antibody meetings promises to be one of the most comprehensive industry information, business development, and networking extravaganzas ever offered on this topic. Sponsored by Strategic Research Institute, the meeting will consist of four events: Antibody Discovery and Preclinical Drug Development, February 24-26; Antibody Clinical Development and Marketing, February 24-26; Trends in Antibody Deal-Making and Financing, February 27-28; and Macromolecule Production and Economics, February 27-28.

The summit features more than 100 speakers, dozens of exhibits, and will draw more than 600 attendees. Research advances, emerging therapeutics, new technologies, antibody marketing, clinical cost optimization, production economics, large-scale manufacturing, partnering and financing topics, intellectual property, and the latest in the clinical pipeline are some of the summit highlights.

For more information, contact Mark Alexay, Strategic Research Institute, at 212-967-0095, ext. 251, e-mail malexay@srinstitute.com, or visit www.srinstitute.com.

February
24

February 24-26, 2003, Hyatt Regency Penn's Landing — Philadelphia
Regulatory I: The IND Phase

Drug and biological products are the focus of this Drug Information Association training course. The objectives of the session are to provide an understanding of the role of regulatory affairs within the pharmaceutical industry, an understanding of the role of the FDA regulators, the ability to plan, design, and organize an IND, and an understanding of how to communicate with the FDA effectively.

The course is designed for people with a background in preclinical research, clinical research, or academia who have just entered the area of regulatory affairs and have zero to six months of experience in regulatory affairs.

This course also will be beneficial to those who are in clinical research, data processing, biostatistics, basic research, project management, and marketing, who would like to gain a better understanding of the regulation of investigational new drugs and biologics.

For more information, contact Dori Browning, Jenna Hannum, or Susan McLaughlin at 215-442-6100, e-mail training@diahome.org, or visit www.dia-home.org.



February
25

February 25-28, 2003, Harvard School of Public Health — Boston
Building Clinical and Administrative Trust: Advance Your Mission and Improve Your Margin

The first day of the conference will focus on two critical issues in trust: medical errors and privacy/HIPAA. Both issues will be explored as causes of distrust and significant areas of strategic opportunities in quality improvement. The second day will address the central role of care providers in building trust in the healthcare system, including presentations about the role of physicians and others on building (or eroding) trust, a case study on the ethics of trust, and a dialog among the faculty on building clinical trust.

For more information, contact Marilyn Barker at 617-384-8676, e-mail mbarker@hsph.harvard.edu, or visit www.hsph.harvard.edu.

February
26

February 26-27, 2003, Hyatt Regency Hotel — Irvine, Calif.
Investment In Innovation: A Preview of Early-Stage Medical Technology Companies

Medtech Insight LLC is the host of the Investment In Innovation conference — a forum for senior executives in the medical device and investment community to preview early-stage medical technology companies in need of funding, acquisition, and/or strategic partnership. The two-day event will showcase more than 50 innovative, emerging medical start-up companies who will present to an audience of 300 senior executives, representing the top medical technology and investment firms. Presenting companies represent a wide range of emerging medical technology markets, in the fields of cardiology and cardiovascular surgery, orthopedics and spine surgery, endoscopic surgery, drug delivery, and stroke management.

For more information, contact Scott Pantel at 714-596-5353, e-mail scott@medtechinsight.com, or visit www.medtechinsight.com.

PLANNING AHEAD

March
2

March 2-4, 2003, Walt Disney World Yacht and Beach Club Resort — Orlando, Fla.
Marketing Research to Support Out-of-the-Box Marketing

The Pharmaceutical Marketing Research Groups 2003 Spring Conference will feature two keynote speakers: Seth Godin, author of Permission Marketing, and Laura Ries, who recently co-authored with her father, Al Ries, The Fall of Advertising and the Rise of PR.

The conference will feature a dynamic program over two days. On the first day, content will focus on the topic of "e" (electronic media) initiatives, and the second day will examine public-relations programming in the pharmaceutical industry. Both days will offer practical information on the marketing research necessary to support such innovative approaches to marketing.

For more information, contact Stephanie Reynders, CLT Meetings International, at 407-628-9700, e-mail sreynders@cltmeetings.com, or visit www.pmr.org.

March
17

March 17-18, 2003 — Washington, D.C.
Healthcare Best Compliance Practices Forum

The Best Practices process is an established peer-review process identifying best practices in key compliance areas. Identified best practices are presented at the forum, the only national event in which healthcare leaders, top government officials, compliance professionals, and legal and academic experts meet in to address practical compliance concerns.

For more information, contact Daniel R. Reardon, Health Ethics Trust/Council of Ethical Organizations, at 703-683-7916, e-mail drreardon@corporateethics.com, or visit www.corporateethics.com.

March
18

March 18-19, 2003, Hyatt Regency Hotel — Princeton, N.J.
4th Annual Multicultural Pharmaceutical Marketing, Media, and PR

The next wave for DTC and OTC advertisers is to get a handle on the surging multicultural market opportunity. This forum will help uncover new market opportunities to reach consumers from ethnic groups with purchasing power who need both treatments and health education for diseases such as CAD, cancer, diabetes, and HIV/AIDS. Effective multicultural marketing can help pharmaceutical brands build long-lasting relationships with a growing base of multicultural consumers.

For more information, contact Rupa Ranganathan at 212-967-0095, ext. 252, e-mail rranganathan@srinstitute.com, or visit www.srinstitute.com.

March
19

March 19, 2003, Lehigh University, College of Business and Economics — Bethlehem, Pa.
Pharma R&D Productivity: Concerns and Viable Solutions

Answers to questions regarding declining R&D productivity can be found at the "Pharma R&D Productivity: Concerns and Viable Solutions" conference. Hosted by the Martindale Center in the College of Business and Economics at Lehigh University, the conference will present a variety of views from industry leaders as to the causes and available solutions to meet this problem. Opening remarks from Dr. Frank L. Douglas, chief scientific officer and executive VP for drug innovation and approval at Aventis SA, will set the tone for the conference. Attendees can look forward to engaging dialog from several noted speakers and perspectives from industry consultants Deloitte & Touche and Ernst and Young.

For more information, contact Rosemary Krauss, Martindale Center, 610-758-4771, or e-mail rhk0@lehigh.edu.

March
24

March 24-25, 2003, Hilton La Jolla Torrey Pines Hotel — La Jolla, Calif.
siRNA in Drug Discovery and Development

Small interference RNAs (siRNAs) have gained much attention in drug discovery and development due to their powerful ability in selective gene silencing. The Small Interference RNA Conference and Exposition will these address issues such as: what are the challenges and hurdles in siRNA industry? How will big pharmaceutical companies integrate and utilize the technology in accelerating drug development? How will smaller biotech companies specialized in siRNAs make creative deals and partnerships? What are the bottlenecks in realizing commercial value? What are intellectual property landscapes? The event will feature senior executives from large pharma and biotech as well as siRNA therapeutic companies, reagent companies, and functional genomic companies.

For more information, contact Mark Alexay, Strategic Research Institute, at 212-967-0095, ext. 251, e-mail malexay@srinstitute.com, or visit www.srinstitute.com.

March
26

March 26-28, 2003, Washington Hilton & Towers — Washington, D.C.
6th National HIPAA Summit

The HIPAA Summit conference series provides a road map to understanding the complex requirements of federal and state law and illuminates strategies for compliance. The summit will provide the most up-to-date information on the status and construction of the HIPAA regulations through presentations of regulators from the Department of Health and Human Services. There will be in-depth analysis of the healthcare privacy and security laws of a number of states, as well as a focus on practical case studies from the field, featuring presentations by leading privacy, security, and compliance officers.

For more information, contact Paul Tunnecliff at 800-684-4549, e-mail registrationhq@aol.com, or visit www.hipaasummit.com.



March 31 **March 31 - April 2, 2003, Gaylord Palms Resort — Kissimmee, Fla.**
12th Annual Partnership with CROs and Other Outsourcing Providers Conference

Dr. David Kessler, one of the most visible commissioners of the FDA in recent history, will discuss new drug approval processes in his keynote address at the 12th Annual Partnerships with CROs and Other Outsourcing Providers Conference. Organized by the Institute for International Research, the conference delves into outsourcing and the development of effective clinical partnerships, and is the place where pharmaceutical outsourcing leaders meet to facilitate change and drive results. The event is expected to attract more than 100 exhibitors and 700 clinical development experts.

The event provides an educational and networking forum to promote building and maintaining effective partnerships between pharmaceutical and biotechnology companies and their clinical development outsourcing providers. New sessions for 2003 include:

- CRO market snapshot: perspectives on growth trends;
- CRO/PhRMA initiatives and impacts on industry;
- Controlling the drivers in the escalating costs of healthcare;
- Opportunities and challenges resulting from industry consolidation.

Three new tracks also are planned that will address strategic planning and market assessment: screening, selecting, and contracting; and post-contract management.

For more information, contact Matt Godson at 212-661-3500 ext. 3225, e-mail mgodson@iirusa.com, or visit www.iirusa.com.

March 31 **March 31-April 2, 2003, Jacob K. Javits Convention Center — New York**
International Pharmaceutical Industry Congress

The International Pharmaceutical Industry Congress will feature four events: Interphex, Pharma-IT Expo and Summit, Pharmaceutical Contract Services and Outsourcing Exposition and Conference, and Drug Science and Technology Summit. Each event will feature a program developed for pharmaceutical industry professionals by the industry's most respected education providers.

The Interphex conference, produced by ISPE, the Society of Life Science Professionals, will address manufacturing-related issues such as process technologies, packaging, validation, and FDA regulations. The Pharmaceutical Contract Services and Outsourcing Symposium, also produced by ISPE, will provide the skills needed to manage the outsourcing process.

The Pharma-IT Expo conference, produced by the Institute for International Research, will provide insights on the use of information technology to optimize pharmaceutical business and scientific processes. The Drug Science and Technology conference is produced by Reed Business Information's Scientific Group.

For more information, contact Lisa Tully at 203-353-7035, e-mail lisat@wagged.com, or visit www.pharmacongress.net.

April 2 **April 2-6, 2003, La Fonda Hotel — Santa Fe, N.M.**
Society for Academic CME Spring Meeting

For more information, contact Melinda Steele, Texas Tech University Health Sciences Center, at 806 743-2226, e-mail melinda.steele@ttuh-sc.edu, or visit www.sacme.org.

April 3 **April 3-4, 2003, Hotel-Intercontinental Chicago — Chicago**
BIO Mid-America Venture Forum Conference

Bio Mid-America Venture Forum Conference is a new regional venture conference for the financial communities and biotechnology companies in America's heartland. The conference will showcase the Midwest's most promising seed, early- and late-stage biotechnology products and platform companies.

The states involved in this collaboration include Iowa, Indiana, Illinois, Michigan, Minnesota, Missouri, Ohio, and Wisconsin.

In addition to exposing the Midwest biotechnology scene to premier venture capital firms in the local region, the conference also will bring a national audience comprising the most prestigious firms. These firms will have the opportunity to review top-of-the-line life-sciences companies from all over America.

There will be workshops highlighting trends in the financial markets and biotech companies.

For more information and to register, log onto www.bio.org/midamerica/2003.

April 27 **April 27-30, 2003, Sheraton New Orleans — New Orleans**
The Health Care Compliance Association's Compliance Institute 2003

This event is one of the most comprehensive compliance conferences designed to meet the needs of today's healthcare compliance officers and staff.

The meeting will feature multiple HIPAA and compliance sessions, an expert faculty, developing industry immersion sessions, and will feature sessions on the latest compliance information on the hottest topics and current events. Speakers will include policy makers, enforcement officials, practicing lawyers, and active compliance and privacy officers.

For more information, contact Erin O'Donnell at 888-580-8373, e-mail info@hcca-info.org, or visit www.hcca-info.org.

May 5 **May 5-6, 2003, Grand Hyatt — New York**
Therapeutic Insight 2003

The third annual global pharma and biotech industry conference is devoted to strategies for identifying, developing, and dominating therapeutic franchises.

The conference includes two days of networking, plenary and breakout sessions for executives in licensing and business development, strategic planning, corporate development, and portfolio and franchise management.

For more information, contact DefinedHealth at 973-921-2850, or visit www.definedhealth.com, or contact Communitech Market Intelligence at 914-245-7764, or visit www.cmius.com.

September 8 **September 8-11, 2003, Chicago Hilton and Towers — Chicago**
The 14th Annual Conference of the National Task Force on CME Provider/Industry Collaboration

For more information, contact Regina Littleton at 312-464-4637 or visit www.ama-assn.org/go/cmetaskforce.

September 22 **September 22-24, 2003, Marriott Wardman Park — Washington, D.C.**
2nd Annual Emerging Technologies and Healthcare Innovations Congress

The congress provides healthcare industry executives with an in-depth conference convening clinicians, healthcare industry executives, technology thought leaders, and vendors. These executives will address the impact and promise of technology and innovation on the future of healthcare.

The forum and trade show will address the relevance and role of a wide range of issues, including Web-enabled business processes and medical devices, the telecommunications convergence, and advances in medical and bioinformatics.

For more information, contact Rachael Scheinman at 804-225-7422, ext. 212, e-mail rachael@tethic.com, or visit www.tethic.com.